NOVARTIS

Novartis reported its late-stage pelacarsen trial did not achieve a statistically significant reduction in cardiovascular events despite lowering Lp(a) levels. The setback knocked Amgen shares sharply but Lilly's stock fell only modestly because lepodisiran uses a different mechanism, showed larger Lp(a) reductions in phase 2, and is being tested in a broader patient population. Lilly's strong diabetes and obesity franchises and its VERVE-102 gene‑editing program mitigate the pelacarsen impact, making the Novartis result a potential risk to Lilly's Lp(a) prospects but not a company‑wide game changer. » Więcej na finance.yahoo.com

Novartis reported that del-desiran failed to meet the primary endpoint in a late-stage myotonic dystrophy trial, compounding a recent late-stage failure of pelacarsen and undermining key growth drivers from its Avidity acquisition. Management said it is evaluating the full dataset and will engage regulators, while reaffirming a 5%–6% annual sales-growth target through 2030. A successful remibrutinib program and other pipeline assets are now critical to offsetting upcoming patent expirations and restoring investor confidence. » Więcej na finance.yahoo.com

Artisan manager David Samra is demanding personnel consequences in the Novartis board after the failure of a late‑stage study for a drug acquired in the $12‑billion takeover of Avidity and disappointing results for Pelacarsen. He criticizes the acquisition control processes, calls for a reform of the compensation structure and improvements to the team that reviews acquisitions. Novartis is maintaining its financial guidance, points to a broad pipeline and emphasizes disciplined capital allocation; the stock rose in pre-market trading. » Więcej na de.investing.com